Saturday 17 October 2026
Export ELMD’s income statement to Excel — free account
Electromed, Inc.
ELMD Healthcare Medical Devices
Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025. In the quarter to June 2026, revenue grew 11.6%, EPS grew 57.7% and free cash flow fell 25.2%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
27.42
0.61
−2.18%
Follow ELMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.31 | 27.22 | 19.19 | 30.88 |
P/S ratio |
3.09 | 3.50 | 2.68 | 4.74 | |
P/FCF ratio |
23.38 | 29.39 | 20.68 | 41.80 | |
P/Operating CF |
1,209.05 | 79.59 | 55.30 | 116.78 | |
P/B ratio |
4.57 | 5.30 | 3.91 | 6.48 | |
Price to Tangible BV |
4.61 | 5.35 | 3.94 | 6.52 | |
EV/Sales |
2.89 | 3.31 | 2.46 | 4.48 | |
EV/EBITDA |
16.20 | 17.72 | 12.16 | 22.09 | |
EV/Operating CF |
20.68 | 25.00 | 16.75 | 34.18 | |
EV/FCF |
21.90 | 27.85 | 18.97 | 39.49 | |
Quick Ratio |
4.46 | 4.27 | 4.43 | 4.21 | |
Current Ratio |
5.09 | 4.86 | 4.91 | 4.69 | |
Net Debt/EBITDA |
(4.82) | (3.56) | (4.19) | (4.99) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.29 | 1.28 | 1.28 | 1.23 | |
Operating CF/Net income |
0.08 | 1.10 | 1.16 | 0.88 | |
Capex/Depreciation |
(1.03) | (2.54) | (0.54) | (0.82) | |
Research and Development Expense of Revenue |
1.43% | 2.03% | 1.94% | 1.69% | |
Selling, General and Administrative Expense of Revenue |
60.91% | 57.23% | 56.61% | 57.33% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
2.71% | 3.47% | 4.55% | 3.92% | |
Graham Net Nets |
0.17 | 0.15 | 0.21 | 0.13 | |
Graham Number |
10.83 | 11.50 | 12.82 | 14.19 | |
Earnings Yield |
3.95% | 3.67% | 5.21% | 3.24% | |
Free Cash Flow Yield |
4.28% | 3.40% | 4.84% | 2.39% | |
Revenue per Share |
2.03 | 2.28 | 2.26 | 2.35 | |
Operating CF per Share |
0.02 | 0.37 | 0.42 | 0.36 | |
Capex per Share |
(0.03) | (0.08) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.01) | 0.29 | 0.40 | 0.34 | |
Cash per Share |
1.70 | 1.67 | 2.07 | 2.47 | |
Shareholders Equity per Share |
5.38 | 5.49 | 5.99 | 6.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.38 | 5.49 | 5.99 | 6.53 | |
Free Cash Flow |
(0.10) | 2.37 | 3.32 | 2.77 | |
Working Capital |
35.80 | 36.19 | 40.00 | 45.15 | |
Capital Expenditures |
(0.27) | (0.66) | (0.15) | (0.22) | |
Net Current Asset Value |
35.69 | 36.10 | 39.92 | 45.08 | |
EV/EBIT |
18.41 | 19.90 | 13.47 | 23.80 | |
Capex to Sales |
0.02 | 0.03 | 0.01 | 0.01 | |
Price to Operating Income |
19.66 | 21.00 | 14.68 | 25.19 | |
| Other line items | |||||
Average Receivables |
23.66 | 24.77 | 26.32 | 28.02 | |
Average Payables |
2.46 | 1.91 | 2.24 | 2.66 | |
Average Inventory |
3.60 | 3.27 | 3.13 | 3.49 | |
Average Assets |
51.26 | 53.59 | 55.96 | 60.03 | |
Average Common Equity |
43.12 | 44.52 | 46.55 | 48.59 |
Columns are period end dates